US-Pharmakonzern Bristol-Myers profitiert weiter von Celgene-Übernahme

NEW YORK (dpa-AFX) – Die Übernahme des Biopharmaspezialisten Celgene beschert dem US-Pharmakonzern Bristol-Myers Squibb (BMS …
(Orginal – Story lesen…)

This website stores some user agent data. These data are used to provide a more personalized experience and to track your whereabouts around our website in compliance with the European General Data Protection Regulation. If you decide to opt-out of any future tracking, a cookie will be set up in your browser to remember this choice for one year. I Agree, Deny
654